Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Neuralstem: Dr. Eva Feldmanís Latest Presentation on The Use of CURís Stem Cells in ALS (CUR, Buy, $4.04)

Overview
Dr. Eva Feldman is the lead investigator for the clinical trials of Neuralstemís (CUR) NSI-566 spinal cord stem cells in…
Read more…

Neuralstem (CUR, Buy, $4.48) Publishing of Phase 1 Results in Annals of Neurology Causes Price Surge (Paid Subscribers Only)

Introduction

The final results of the phase 1 trial of Neuralstemís (CUR) NSI-566 spinal cord stem cells in the treatment of…
Read more…

Neuralstem: Evidence Increasingly Suggests its Neural Stem Cells are Effective in ALS (CUR, $2.57)

Thoughts on the Stock Price
I have been recommending Neuralstem†(CUR) since my initiation report†of November 5, 2012 at a price of…
Read more…